RCUS Q1 2021 Earnings — Arcus Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

RCUSArcus Biosciences, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+440.6% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$73M-768.9% margin

Net Income

-$73M-767.3% margin

EPS (Diluted)

$-1.08

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

-$66M

Free Cash Flow

-$70M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$935M

Total Liabilities

$270M

Stockholders' Equity

$665M

Cash & Equivalents

$390M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$2M	+440.6%
Gross Profit	$9M	$2M	+440.6%
Operating Income	-$73M	-$28M	-156.2%
Net Income	-$73M	-$28M	-161.6%

Revenue Segments

Gilead Access Rights

$8M82%

Taiho Collaboration Agreement

$2M18%